Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines

Teng, WeiWeiTengChang, Ting-TsungTing-TsungChangYang, Hwai-IHwai-IYangPeng, Cheng-YuanCheng-YuanPengSu, Chien-WeiChien-WeiSuTUNG-HUNG SUHu, Tsung-HuiTsung-HuiHuYu, Ming-LungMing-LungYuHUNG-CHIH YANGWu, Jaw-ChingJaw-ChingWu2022-09-292022-09-292021-121936-0533https://scholars.lib.ntu.edu.tw/handle/123456789/623271ALT ≥ 80 U/L and HBV DNA ≥ 2000 IU/ml are treatment criteria of APASL guidelines for chronic hepatitis B (CHB) patients. The need of antiviral therapy for patients in gray zone (ALT < 80 U/L or HBV DNA < 2000 IU/ml) is controversial. This study aimed to develop a scoring system to predict hepatocellular carcinoma (HCC) and evaluate the benefit of antiviral therapy in these patients.enAntiviral therapy; Benefits; Family history; Gray zone; Hepatitis B virus; Hepatocellular carcinoma; Noncirrhosis; prediction; Risk score; Treatment guidelinesRisk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelinesjournal article10.1007/s12072-021-10263-x347417232-s2.0-85118575810WOS:000715018800001https://api.elsevier.com/content/abstract/scopus_id/85118575810